2023
DOI: 10.1158/1535-7163.c.6539547
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Data from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer

Abstract: <div>Abstract<p>Endocrine therapy is important for management of patients with estrogen receptor (ER)–positive breast cancer; however, positive ER staining does not reliably predict therapy response. We assessed the potential to improve prediction of response to endocrine treatment of a novel test that quantifies functional ER pathway activity from mRNA levels of ER pathway–specific target genes. ER pathway activity was assessed on datasets from three neoadjuvant-treated ER-positive breast cancer p… Show more

Help me understand this report
View published versions

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles